Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a leading biotechnology company headquartered in Carlsbad, California. Founded in 1989, Ionis has been pioneering the discovery and development of antisense drugs, with an impressive portfolio of over 1300 patents. Ionis focuses on creating innovative RNA-targeted therapies for complex diseases, particularly in the areas of cardiovascular, metabolic, neurological, and rare genetic disorders.
Ionis has successfully brought several groundbreaking medicines to market. Notable achievements include the development of Spinraza, in collaboration with Biogen, which was launched in 2016 to treat spinal muscular atrophy, a rare neuromuscular disorder. In 2023, Biogen also launched Qalsody for ALS, further extending the impact of Ionis' antisense technology.
Through its cardiovascular-focused subsidiary, Akcea Therapeutics, Ionis has introduced drugs like Tegsedi for ATTR amyloidosis and Waylivra in Europe for cardiology indications. The company continues to advance its pipeline with promising candidates such as olezarsen, an investigational RNA-targeted therapy for familial chylomicronemia syndrome (FCS). Ionis' ongoing Phase 3 trials for olezarsen have shown promising results, with significant reductions in triglyceride levels and improvements in related health outcomes.
Ionis' commitment to innovation and patient care is also evident in its robust financial health and strategic partnerships. With a deep understanding of disease biology and cutting-edge technology, Ionis continues to drive advancements in RNA therapies and gene editing, aiming to deliver life-changing medicines for patients around the world.
Recently, Ionis announced positive clinical trial results for several of its investigational drugs and plans to pursue regulatory approvals for these therapies. The company's pipeline is well-positioned to address unmet medical needs in various therapeutic areas, promising a steady flow of new treatments in the coming years.
For more detailed information about Ionis Pharmaceuticals, its products, and career opportunities, visit their official website at www.ionispharma.com.
The Phase 3 VALOR study of tofersen, an investigational therapy for SOD1-ALS, revealed that early initiation significantly slowed declines in clinical function, respiratory function, muscle strength, and quality of life. The 12-month data demonstrated a 33% reduction in SOD1 protein levels and a 51% decrease in neurofilament, indicating reduced neurodegeneration. Additionally, early initiation was correlated with a lower risk of death or permanent ventilation. However, the initial six-month study did not meet its primary endpoint.
Ionis Pharmaceuticals (Nasdaq: IONS), located in Carlsbad, Calif., will present at the RBC Capital Markets Global Healthcare Conference on May 18, 2022. A live webcast of the presentation will be available on Ionis's website, with a replay accessible within 48 hours after the event. Ionis has over 30 years of experience in RNA-targeted therapy and boasts a strong pipeline focusing on cardiovascular and neurological franchises.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) reported a strong start to 2022, achieving $142 million in total revenues for Q1, representing over 25% growth year-over-year. The firm remains on track to meet its 2022 financial guidance. Key highlights include positive data from studies of eplontersen, ION449, and donidalorsen. Operating expenses totaled $173 million on a non-GAAP basis, yielding a net loss of $39 million. Ionis maintains a robust cash position with $2.1 billion available for continued investments in its late-stage pipeline, positioning the company for future growth.
Ionis Pharmaceuticals (Nasdaq: IONS) will hold its 2022 virtual Annual Meeting of Stockholders on June 2, 2022. The schedule includes a brief stockholder meeting at 5:00 p.m. ET, where eligible stockholders can participate via a live webcast. Stockholders must use their proxy cards to access the meeting. Following this, a corporate update will be presented by CEO Brett P. Monia at 5:30 p.m. ET, accessible to all interested parties. Details for participation and additional resources are available on Ionis' website.
Ionis Pharmaceuticals (Nasdaq: IONS) will host a live webcast on May 4, 2022, at 11:30 a.m. Eastern Time to discuss its first quarter financial results and update on pipeline and business progress. This event follows over 30 years of Ionis's leadership in RNA-targeted therapies, with three marketed medicines and a strong late-stage pipeline focusing on cardiovascular and neurological areas. Access the webcast and replay details at ionispharma.com.
Ionis Pharmaceuticals and AstraZeneca announced positive results from the ETESIAN Phase 2b study of ION449 (AZD8233), aimed at reducing cholesterol in patients with hypercholesterolemia. The study met its primary endpoint, achieving a 79% reduction in LDL-C levels, with both treatment doses (50mg and 90mg) showing significant efficacy. The trial also confirmed a reduction in PCSK9 levels by up to 94%. ION449 was well tolerated, and the results support further clinical development as a potential next-generation treatment for patients at high cardiovascular risk.
Biogen and Ionis Pharmaceuticals announced the Phase 1 study results of BIIB078, an investigational drug for C9orf72-associated ALS. The study, involving 106 participants, found that BIIB078 did not demonstrate any clinical benefit and failed to meet secondary efficacy endpoints. As a result, the clinical program for BIIB078 will be discontinued. Although well-tolerated, the study highlighted that the disease mechanism is more complex than initially hypothesized. Both companies remain committed to advancing ALS research and addressing this neurodegenerative disease.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced its participation in several upcoming investor conferences. Key events include:
- Stifel 2022 Virtual CNS Days on March 28, 2022
- Guggenheim Virtual Genomic Medicines and Rare Disease Day on April 1, 2022
- Needham 21st Annual Virtual Healthcare Conference on April 11, 2022
- Bank of America 2022 Healthcare Conference on May 11, 2022, in Las Vegas, NV
Ionis Pharmaceuticals has published positive Phase 2 results for donidalorsen, an investigational treatment for hereditary angioedema (HAE). The study showed a 90% reduction in angioedema attacks with 80 mg monthly doses compared to placebo, alongside significant improvement in quality of life. The treatment was well-tolerated with no serious adverse events noted. These findings support the ongoing Phase 3 study for donidalorsen, emphasizing Ionis' commitment to addressing unmet medical needs in HAE patients.
Ionis Pharmaceuticals (Nasdaq: IONS) announced it is accepting applications for the Janice Wiesman Young Investigator Grant Program, honoring Dr. Wiesman for her contributions to understanding transthyretin amyloidosis (ATTR). The program offers $50,000 annually for two years to U.S. researchers advancing ATTR knowledge, with applications due by April 4, 2022. The inaugural grants were awarded to Dr. Trejeeve Martyn and Dr. Jeremy Slivnick for their research on cardiac amyloidosis. March is also recognized as Amyloidosis Awareness Month, highlighting the disease's significance.
FAQ
What is the current stock price of Ionis Pharmaceuticals (IONS)?
What is the market cap of Ionis Pharmaceuticals (IONS)?
What does Ionis Pharmaceuticals specialize in?
Where is Ionis Pharmaceuticals located?
What are some key products developed by Ionis Pharmaceuticals?
What is the latest development in Ionis' pipeline?
Who are some of Ionis' key partners?
How does Ionis Pharmaceuticals contribute to RNA therapy innovation?
What is olezarsen and what does it treat?
How can I learn more about career opportunities at Ionis Pharmaceuticals?
What recent clinical trials has Ionis Pharmaceuticals announced?
How does Ionis Pharmaceuticals support patients with rare diseases?
